Proactive Investors - Run By Investors For Investors

Managed access programmes offer an alternative way forward for drug companies

Eighteen of the top 20 big pharmaceutical companies now provide early access to their drugs
researcher filling a vial
Merck ran a programme for cancer immuno-therapy Keytruda that formed an invaluable part of the regulatory filing

Managed access programmes (MAPs) have been around for some time, offering poorly people access to drugs that aren’t currently fully licensed or are unavailable in a particular country.

Patients often receive the new, unapproved medication on compassionate grounds, while the MAPs themselves tend to be overseen by specialist drugs firms.

Here in the UK, Clinigen has run over 250 programmes providing ‘off-label’ treatments to those in acute medical need.

Eighteen of the top 20 big pharmaceutical companies now provide early access to their drugs.

Source of rich data 

In fact, MAPs are becoming a rich data source with patient-reported outcome information bundled up with the stats gleaned from clinical trials, which is then submitted to the regulator.

“Merck ran a MAP programme for Keytruda that formed an invaluable part of the regulatory filing that they were able to get reimbursement on,” said Tim McCarthy, chairman of ImmuPharma (LON:IMM).

Keytruda is one of a new breed of immunotherapy drugs that could help revolutionise the treatment of the killer disease.

McCarthy’s reference to the Merck breakthrough was by way of example as of what can be achieved using MAPs as ImmuPharma prepares to go down the same route.

500 patients to be treated

It will offer 500 patients with the autoimmune disease lupus access to Lupuzor, which generated mixed data in phase III clinical trial.

“We can get valuable data on the drug,” McCarthy told Proactive’s, Andrew Scott.

“We call this real-world data. I should stress, this is not a clinical study. All patients will get the drug, there will be no comparator group, blinding or randomisation.”

The MAP will be around a tenth of the cost of the last ImmuPharma clinical with patients receiving the medication free of charge for two years.

“This approach is getting a lot of traction now in our industry,” said McCarthy.


Despite the phase III setback for Lupuzor, ImmuPharma still plans to make a regulatory filing.

View full IMM profile View Profile

ImmuPharma PLC Timeline

Related Articles

scientist in lab
September 25 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients
tumour cells
July 25 2018
Sign-off by the US Food & Drug Administration is considered the "global standard for approval", the company said
October 19 2018
Respiratory syncytial virus causes the common cold, for which there is no effective cure.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use